key: cord-1007063-yx5h30jd
authors: Jin, Woo Jung; Ahn, Sang Woo; Jang, Seung Hee; Hong, Seong Min; Seol, Jung Eun; Kim, Hyojin
title: Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination
date: 2021-10-28
journal: J Dermatol
DOI: 10.1111/1346-8138.16212
sha: 4d413640ddc21d563f8307910df9ca4f4c73a9fc
doc_id: 1007063
cord_uid: yx5h30jd

nan

Dear Editor,

The ChAdOx1 nCoV-19 vaccine (AstraZeneca ® ; UK) has been administrated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Injection-site skin reaction has been reported as a common adverse drug reaction; however, there has been only one report of vasculitis so far with the ChAdOx1 nCoV-19 vaccine. 1 Herein, we present a case of new-onset leukocytoclastic vasculitis following ChAdOx1 nCoV-19 vaccination.

A 68-year-old Korean woman presented with asymptomatic erythematous to purpuric non-blanching macules on both lower extremities for 2 days (Figure 1a 

Smallvessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2

Skin manifestations associated with COVID-19: Current knowledge and future perspectives

Possible association between IgA vasculitis and COVID-19

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2-vaccine -a case report